Related Experiment Video
Updated: Feb 7, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
GRIN3A defines an immunosuppressive niche in advanced prostate cancer
Xinglin He1,2,3, Yaohua Hu2, Zhite Zhao3
1Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xi'an, 710000, Shaanxi, China.
Abstract:
Early-stage prostate cancer is typically manageable with standard therapies, yet the eventual development of castration-resistant prostate cancer (CRPC) remains a significant barrier to effective clinical management. Specifically, the response to immunotherapy in CRPC remains limited, primarily due to a lack of predictive biomarkers and specific therapeutic targets. This study systematically integrates single-cell transcriptomic data across various disease stages, coupled with multi-dimensional validation, to reveal that glutamate ionotropic receptor NMDA type 3A (GRIN3A) expression is persistently elevated throughout tumor evolution and correlates significantly with advanced pathological stages and poor prognosis. Notably, during the transition to CRPC, tumor subpopulations with high GRIN3A expression exhibit pronounced immunoregulatory properties. Experimental validation demonstrated that GRIN3A levels inversely correlate with T-cell infiltration and promote an immunosuppressive microenvironment, partially mediated by TGF-β signaling activation. Furthermore, GRIN3A expression predicts the efficacy of immune checkpoint blockade (ICB) therapy and sensitivity to multiple chemotherapeutic agents. Collectively, these results suggest that GRIN3A has the potential to serve as a biomarker for tumor heterogeneity and immunotherapy resistance, providing a rationale for further exploration of strategies to overcome immune evasion in advanced PCa.
Insights
Glutamate receptor GRIN3A is elevated in advanced prostate cancer, driving immune evasion and resistance to immunotherapy. Targeting GRIN3A may improve treatment outcomes for castration-resistant prostate cancer (CRPC).
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Castration-resistant prostate cancer (CRPC) poses challenges due to limited immunotherapy response.
- Lack of predictive biomarkers and therapeutic targets hinders effective CRPC treatment.
- Understanding tumor evolution and immune microenvironment is crucial for CRPC management.
Purpose of the Study:
- To identify novel biomarkers and therapeutic targets in advanced prostate cancer.
- To investigate the role of GRIN3A in CRPC progression and immune evasion.
- To evaluate GRIN3A as a predictor of treatment response.
Main Methods:
- Systematic integration of single-cell transcriptomic data across disease stages.
- Multi-dimensional validation of identified molecular targets.
- Experimental assessment of GRIN3A function in tumor microenvironment and treatment sensitivity.
Main Results:
- GRIN3A expression is persistently elevated in prostate cancer, correlating with advanced stages and poor prognosis.
- High GRIN3A expression in CRPC subpopulations is linked to immunoregulatory properties and an immunosuppressive microenvironment.
- GRIN3A levels inversely correlate with T-cell infiltration and are partially mediated by TGF-β signaling.
- GRIN3A expression predicts response to immune checkpoint blockade (ICB) and chemotherapy.
Conclusions:
- GRIN3A serves as a potential biomarker for tumor heterogeneity and immunotherapy resistance in prostate cancer.
- Targeting GRIN3A may offer a strategy to overcome immune evasion in advanced prostate cancer.
- Further research into GRIN3A-targeting therapies is warranted for CRPC treatment.
Related Concept Videos
Ecological Niches
Stem Cell Niche
Defining Psychology
Piecewise-Defined Functions
Defining Social Psychology
Rules for Defining Functions

